Abarelix (CAS 183552-38-7) – GMP Manufacturer

DescriptionAbarelix (CAS 183552-38-7) is a synthetic decapeptide and a potent gonadotropin-releasing hormone (GnRH) antagonist. It functions by binding to and blocking the GnRH receptor in the anterior pituitary gland, inhibiting the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This suppression leads to a decrease in testosterone production, which is crucial for the growth of hormone-sensitive prostate cancer cells. Abarelix is utilized in research to study its effects on hormone regulation and prostate cancer treatment mechanisms. Synthesized under GMP conditions with a purity of ?99.90%, it ensures high-quality material for pharmaceutical and biochemical research. Contents hide 1 Product Specifications 2 Mechanism of Action & Research Applications 3 Disclaimer Product SpecificationsParameterDetailsProduct NameAbarelixSynonymsPPI-149, R3827CAS No.183552-38-7Purity?99.90%Molecular FormulaC??H??ClN??O??Molecular Weight1416.10 DaAppearanceWhite to off-white powderSolubilitySoluble in water and DMSOStorage ConditionsStore at –20?°C; protect from light and moistureManufacturing StandardGMP-compliantApplicationsProstate cancer research, hormone regulation studiesRegulatory StatusFor laboratory research use onlyMechanism of Action & Research ApplicationsAbarelix functions as a potent GnRH antagonist by binding to and blocking the GnRH receptor in the anterior pituitary gland. This action inhibits the secretion of LH and FSH, leading to a decrease in testosterone production. In prostate cancer research, this mechanism is crucial for studying hormone regulation and developing treatment strategies for hormone-sensitive cancers. Its high purity and GMP manufacturing ensure reliability in experimental settings.DisclaimerThis product is intended strictly for laboratory research use only. It is not approved for human or veterinary use. Please adhere to institutional safety protocols when handling.